Jul 06, 2010 (Datamonitor via COMTEX) –

Daiichi Sankyo and Ranbaxy Laboratories, a research based pharmaceutical company, have announced that Ranbaxy’s new drug discovery research, or NDDR, has been transferred to Daiichi Sankyo India Pharma as part of the strategy to strengthen the global R&D structure of the Daiichi Sankyo Group.

The transaction has been reportedly approved by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India.

The new organization, Daiichi Sankyo Life Science Research Center (RCI) in India based in Gurgaon will play a key role in the group’s global drug discovery research – to create new drugs, especially in the area of low molecular weight infectious and inflammatory disease treatments. RCI will also reportedly continue to support the programs of dengue and tuberculosis that NDDR was working on in alliance with the department of biotechnology, Ministry of Science and Technology, Government of India.

Joji Nakayama, president and CEO of Daiichi Sankyo, said: “With the transfer of the NDDR into the Daiichi Sankyo Group’s pharmaceutical R&D organization, we will further strengthen our integrated global research capabilities through the addition of talented researchers who offer a new perspective and have a wealth
of imagination and experience. We look forward to achieving outstanding and innovative results based on the implementation of global research management throughout our highly diversified and global R&D structure.”